Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

and the, AIBL Research Group

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

Original languageEnglish
Pages (from-to)60-72
Number of pages13
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume8
DOIs
StatePublished - 2017

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Blood

Fingerprint Dive into the research topics of 'Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort'. Together they form a unique fingerprint.

  • Cite this